Immuron Limited (IMRN): Price and Financial Metrics
IMRN Price/Volume Stats
| Current price | $2.45 | 52-week high | $5.96 |
| Prev. close | $2.41 | 52-week low | $1.48 |
| Day low | $2.42 | Volume | 4,963 |
| Day high | $2.45 | Avg. volume | 837,018 |
| 50-day MA | $2.39 | Dividend yield | N/A |
| 200-day MA | $2.03 | Market Cap | 13.97M |
IMRN Stock Price Chart Interactive Chart >
Immuron Limited (IMRN) Company Bio
Immuron Limited focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company was founded in 1994 and is based in Australia.
Latest IMRN News From Around the Web
Below are the latest news stories about IMMURON LTD that investors may wish to consider to help them evaluate IMRN as an investment opportunity.
Immuron Clinical Trials UpdateHighlights: US Naval Medical Research Command (NMRC) campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information package has been completedPre-IND submission to the U.S. Food and Drug administration (FDA) planned for H1 2024 Travelan® clinical study inpatient phase completed and 6 month follow up visits planned MELBOURNE, Australia, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian base |
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical StudyHighlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting volunteers against moderate to severe campylobacteriosisNew CampETEC product is a prophylactic therapeutic designed to protect against Campylobacter and Enterotoxigenic Escherichia coli (ETEC) infections, two of the major causes of Travelers’ diarrhea The in-patient stage of the study is anticipated to be |
Immuron CEO, Steven Lydeamore Investor Webinar PresentationMELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar “Coffee Microcaps Morning Meeting”, to be held on Thursday, 30th of November, 2023, 9:00am ADEST. CEO Steven Lydeamore will provide an overview and update on the business and upcoming milestones. Following the presentation, attendees will have the opportunity to ask q |
Immuron Announces Travelan® Clinical Study Cohort 2 commencesHighlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced the second cohortThe clinical study 6 month follow up of Cohorts 1 and 2 anticipated to be completed in April 2024Travelan® is known to protect against the onset of Traveler’s diarrhea (TD), the most common illness reported by travelers MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Immuron Limit |
Immuron achieves record quarterly Travelan® salesHighlights: Record quarterly Travelan® sales of $1,550,240Total sales of A$1,565,767 in Q1, FY24 $1,508,933 increase on Q1, FY23 sales130% higher than pre-pandemic period Q1, FY20 sales MELBOURNE, Australia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record quarterly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplemen |
IMRN Price Returns
| 1-mo | -7.89% |
| 3-mo | 36.11% |
| 6-mo | 42.44% |
| 1-year | 23.53% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 30.67% |
| 2023 | -9.86% |
| 2022 | -16.80% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Continue Researching IMRN
Want to see what other sources are saying about Immuron Ltd's financials and stock price? Try the links below:Immuron Ltd (IMRN) Stock Price | Nasdaq
Immuron Ltd (IMRN) Stock Quote, History and News - Yahoo Finance
Immuron Ltd (IMRN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...